Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangxi Rimag Group Co., Ltd.
江西一脈陽光集團股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2522)

VOLUNTARY ANNOUNCEMENT
INCREASE IN SHAREHOLDING IN H SHARES OF THE COMPANY BY CERTAIN DIRECTORS

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Jiangxi Rimag Group Co., Ltd. (the "**Company**", together with its subsidiaries collectively referred to as the "**Group**") on a voluntary basis.

On November 4, 2025, the Board was informed that the following Directors of the Company (collectively, the "**Relevant Directors**") purchased in aggregate 96,500 H shares of the Company in the open market with their own funds on November 3 and 4, 2025 (the "**Increase in Shareholdings**"): (i) Mr. CHEN Zhaoyang, the chairman of the Board, an executive Director and the chief executive officer; (ii) Ms. HE Yingfei, an executive Director, a vice president, the joint company secretary and the secretary to the Board; and (iii) Mr. FENG Xie, an executive Director, a vice president and the chief financial officer. The Relevant Directors have informed the Board that their decision on the Increase in Shareholdings was made based on their recognition of the Group's recent phased development achievements in areas such as regional medical imaging sharing centers and medical imaging data services, and the Group's professional capabilities and R&D technology demonstrated in building a comprehensive smart medical imaging industry chain of "Data + AI/ Algorithms + Application Scenarios". At the same time, given that the Group's strategic layout in innovative fields is highly aligned with the "Implementation Opinions on Promoting and Regulating the Application Development of "Artificial Intelligence + Healthcare" (Guofa [2025] No. 11) (《關於促進和規範"人工智能+醫療衛生"應用發展的實施意見》(國發[2025]11號)) issued by the State Council on November 4, 2025, among other documents, they have strong confidence in the Group's future development prospects. The Relevant Directors believe the current price of H shares of the Company does not fully reflect the Group's long-term investment value. In addition, according to the information available to the Company and to the best knowledge of the Board, after the Increase in Shareholdings and up to the date of this announcement, the Company continues to maintain sufficient public float as required by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jiangxi Rimag Group Co., Ltd.
江西一脈陽光集團股份有限公司
Mr. CHEN Zhaoyang
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, November 4, 2025

As at the date of this announcement, the Board comprises Mr. CHEN Zhaoyang, Ms. HE Yingfei, Mr. FENG Xie and Mr. LI Feiyu as executive Directors, Mr. LIU Senlin and Mr. GUO Tao as non-executive Directors, and Mr. WU Xiaohui, Mr. LUO Yi and Ms. CHEN Yifei as independent non-executive Directors.